The Sema4 Solid Tumor Panel uses next-generation sequencing (NGS) technology to analyze 161 of the most relevant cancer driver genes. This panel facilitates the detection of actionable mutations in solid tumor cancers, including lung cancer, colorectal cancer, skin cancer (melanoma), breast cancer, brain cancer, and thyroid cancer.


Highly accurate >99% sensitivity and specificity*
Comprehensive >99% of guideline-recommended genes tested
Actionable Delivers insights to guide targeted therapy or clinical trial selection
Advanced Powered by the Oncomine platform, a next-generation sequencing solution used by leading global research institutions and clinical trials, including the NCI-MATCH trial

*Compared against a series of cases with known or previously-tested mutations by other NGS methods.